Company Overview
Company Type: Public Company
Website: www.havnlife.com
Number of Employees: -
Ticker: HAVN (CNSX)
Year Founded: 2020


Business Description
HAVN Life Sciences Inc., a biotechnology company, engages in the research and development of psychopharmacological products from plants and fungi. The Company also focuses on developing methodologies for the standardize and quality-controlled extraction of psychoactive compounds from plants and fungi, including Psilocybe spp. mushrooms; and the genera directive compounds, such as psilocybin, psilocin, and baeocystin, as well as the development of natural health care products from non-regulated compounds. The company was incorporated in 2020 and is headquartered in Richmond, Canada.

Financial Information (Currency: CAD, in mm) 
Total Revenue
0.6
Market Capitalization
0.8
TEV/Total Revenue
1.4x
EBITDA
(3.5)
Total Enterprise Value
0.8
TEV/EBITDA
NM
EBIT
(3.6)
Cash & ST Invst.
0.0
P/Diluted EPS Before Extra
NM
Net Income
(15.7)
Total Debt
0.0
Price/Tang BV
0.5x
Capital Expenditure
0.0
Total Assets
1.4
Total Debt/EBITDA
NM
Currency in CAD in mm, LTM as of Jan-31-2023 TEV and Market Cap are calculated using a close price as of Sep-27-2023

Key Professionals
Name
Title
Moore, Tim 
Interim CFO, CEO & Chairman
Pozar, Jenna 
Chief Operations Officer
More, Paul 
Controller

Key Board Members
Name
Title
Moore, Tim 
Interim CFO, CEO & Chairman
Casselman, Ivan 
Director
Samuelsson, Alexzander 
Director


Primary Industry Classification
Biotechnology


Primary Office Location
2800-666 Burrard Street | Vancouver, BC | V6C 2Z7 | Canada

Current and Pending Investors
Alpha Blue Ocean Investment Group (Pending)

Stock Quote and Chart (Currency: CAD)
Last  (Delayed)
 0.03
Market Cap (mm)
0.8
Open
 0.03
Shares Out. (mm)
26.6
Previous Close
 0.03
Float %
95.7%
Change on Day
0.00
Shares Sold Short (mm)
-
Change % on Day
0.0%
Dividend Yield %
-
Day High/Low
 0.03/ 0.03
Diluted EPS Excl. Extra Items
(2.20)
52 wk High/Low
 0.15/ 0.02
P/Diluted EPS Before Extra
NM
Volume (mm)
0.0020
Avg 3M Dly Vlm (mm)
0.09
Beta 5Y
(0.72)


 
Delayed Quote** | Last Updated on Sep-27-2023 12:00 AM (GMT-5)
CNSX:HAVN - Common Stock


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Patented Brain Health and Recovery Formulations of Bennett's Choice
As of September 28, 2021, Patented Brain Health and Recovery Formulations of Bennett's Choice was acquired by HAVN Life Sciences Inc. Patented Brain Health and Recovery Formulations of Bennett's Choice comprises natural health product formulations patent. The asset is located in Canada.

United States and Canada
Biotechnology
-
-
-
GCO Packaging and Manufacturing Ltd.
GCO Packaging and Manufacturing Ltd. operates a manufacturing, packaging, and distribution facility. The company was incorporated in 2019 and is based in Surrey, Canada. As of April 7, 2021, GCO Packaging and Manufacturing Ltd. operates as a subsidiary of HAVN Life Sciences Inc.

United States and Canada
Real Estate Operating Companies
-
-
-
HAVN Research Inc.
HAVN Research Inc. operates as a biotechnology research and development company that develops natural health care products. The company was incorporated in 2020 and is based in Vancouver, Canada.

United States and Canada
Biotechnology
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jul-21-2022
-
Private Placement
Target
HAVN Life Sciences Inc. (CNSX:HAVN)
Alpha Blue Ocean Investment Group

6.98
Mar-01-2022
Mar-03-2022
Private Placement
Target
HAVN Life Sciences Inc. (CNSX:HAVN)


1.58
Dec-20-2021
Cancelled
Merger/Acquisition
Buyer
Spore Life Sciences Inc.
HAVN Life Sciences Inc. (CNSX:HAVN)
10784141 Canada Corporation,AB Consulting and Connecting Inc.,F.N. Swaida Dentistry Professional Corporation,Invictus Investments Limited,HG2., Inc.,MJZ Management Inc.,OBAJI Medical Management Inc.,Richard Kimel Professional Corporation,Wetherby Growth 2020 Lp,Dr. Zein Faraj Medicine Professional Corp.,2411037 Ontario Ltd.,2392398 Ontario Inc.,TruGen, LLC
35.28
Oct-4-2021
-
Shelf Registration
Target
HAVN Life Sciences Inc. (CNSX:HAVN)


19.86
Sep-29-2021
Sep-28-2021
Merger/Acquisition
Buyer
Patented Brain Health and Recovery Formulations of Bennett's Choice
HAVN Life Sciences Inc. (CNSX:HAVN)
Bennett's Choice
0.77
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Jul-27-2023
Auditor Changes
HAVN Life Sciences Inc. Announces Change of Auditors
Oct-27-2022
Company Conference Presentations
HAVN Life Sciences Inc. Presents at LD Micro Main Event XV Conference 2022, Oct-27-2022 10:30 AM
Oct-27-2022
Product-Related Announcements
HAVN Life Sciences Inc. Announces Retail Listing with Loblaws Company Ltd
Oct-14-2022
Executive Changes - CFO
HAVN Life Sciences Inc. Announces CFO Changes
Oct-14-2022
Executive/Board Changes - Other
HAVN Life Sciences Inc. Announces Board Changes

M&A Advisors
Cassels Brock & Blackwell LLP


Advisors
Most Recent Auditor
DeVisser Gray LLP
M&A Advisors
Cassels Brock & Blackwell LLP
Private Placement Advisors
H.C. Wainwright & Co., LLC
Public Offering Advisors
Cassels Brock & Blackwell LLP, DeVisser Gray LLP


Most Recent Auditor
De Visser Gray


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
Smart Insider Ltd.

Dec 09, 2020 03:24 AM
HAVN
Havn Life Sciences Inc: 1 director bought
Reporting Results*
1


Ownership Summary

            Top Holders 
Holders by Type
Holder

Common Stock Equivalent Held

% of Total Shares Outstanding

Market Value (CAD in mm)

Position Date


ABO Infinium Americas Opco Ltd.

1,004,000

3.77

0.0

Aug-31-2023


Neufeld CA, CPA, MBA, Victor 

100,000

0.38

0.0

Mar-15-2022


Moore, Tim 

33,333

0.13

0.0

May-26-2022


Leong, Gary Joseph

6,000

0.02

0.0

Mar-23-2022


Clissold FCGA, FCPA, Gordon 

1,017

0.00

0.0

May-26-2022



 



Top Buyers
Buyers
Common Stock Equivalent Held
Change
ABO Infinium Americas Opco Ltd.
1,004,000
1,004,000

Top Sellers
No Top Sellers data available.


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Bacopa Brain, Baeocystin (Future), Chaga Immunity, Consulting Services (Future), Controlled Psychoactive Products (Future), Cordyceps Perform, HAVN Cognitive (Future), HAVN Energy (Future), HAVN Immunity (Future), HAVN Stress (Future), Lion’s Mane, Mind Mushroom, Psilocin (Future), Psilocybe spp (Future), Psilocybin (Future), Reishi Recharge, Rhodiola Relief


Upcoming Events
Date/Time
Type
Oct-06-2023
Estimated Earnings Release Date (S&P Global Derived)
* Future Events are subject to change.


Recent Major Filings

Key Filings
Filed On
Company Name
Source
Form Type
Size
Sep-28-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
News Releases
99 KB
Sep-19-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
News Releases
98 KB
Sep-11-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Securities Acquisition Filings
247 KB
Aug-30-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
News Releases
135 KB
Aug-30-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Material Change Report
117 KB
Aug-15-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Securities Acquisition Filings
306 KB
Jul-27-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
News Releases
131 KB
Jul-27-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Change of Auditor
126 KB
Jul-27-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Change of Auditor
97 KB
Jul-27-2023
HAVN Life Sciences Inc. (CNSX:HAVN)
SEDAR
Change of Auditor
157 KB


Insider Trades
Holder Name
Trade Date Range
Security Type
Transacted Shares
Transaction Value Range (CAD)
Transaction Type
% Change
Source
Clissold FCGA, FCPA, Gordon  (Former CFO & Director)
Apr-01-2022
Common Shares
566
1,307
Open Market Acquisition
125.83
Multiple
Leong, Gary Joseph (Former Director)
Mar-23-2022
Common Shares
3,333
-
Derivative Exercise and Retained Stock
125.00
Multiple
Moore, Tim  (Interim CFO, CEO & Chairman)
Mar-16-2022
Common Shares
16,666
-
Derivative Exercise and Retained Stock
100.00
Multiple
Neufeld CA, CPA, MBA, Victor  (Former Independent Chairman)
Mar-15-2022
Common Shares
33,333
-
Derivative Exercise and Retained Stock
50.00
Multiple
Clissold FCGA, FCPA, Gordon  (Former CFO & Director)
Oct-05-2021
Common Shares
450
3,040
Open Market Acquisition
New
Multiple
-
Oct-05-2021
Common Shares
67
460
Open Market Acquisition
-
Exchange Announcement
-
Oct-05-2021
Common Shares
383
2,580
Open Market Acquisition
-
Exchange Announcement
Excluding Automatic Transactions
Key Board Members Details
Name
Title
Phone
Fax
Email
Moore, Tim 
Interim CFO, CEO & Chairman
-
-

Casselman, Ivan 
Director
-
-

Samuelsson, Alexzander 
Director
-
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Moore, Tim 
Interim CFO, CEO & Chairman
-
-

Pozar, Jenna 
Chief Operations Officer
-
-

More, Paul 
Controller
-
-

* denotes that the relationship is proprietary

Historical Equity Pricing Data supplied by Interactive Data Pricing and Reference Data LLC 
S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 

**Intraday Quotes are delayed by at least 20 minutes.
